GeneDx (WGS) Earnings Date, Estimates & Call Transcripts $122.54 -0.57 (-0.46%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GeneDx Earnings Summary GeneDx released Q2 2025 earnings on July 29, 2025, reporting an EPS of $0.50, which topped the consensus estimate of $0.10 by $0.40. Quarterly revenue was reported to be $102.69 million, above analyst estimates of $86 million. With a trailing EPS of $0.05 and a P/E Ratio of 2,428.88, GeneDx's earnings are expected to grow 115.46% next year, from $0.97 to $2.09 per share. Latest Q2 Earnings DateJul. 29EstimatedConsensus EPS (Jul. 29) $0.10 Actual EPS (Jul. 29) $0.50 Beat By $0.40 Actual Revenue (Jul. 29) $102.69MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)Slide DeckFull Screen Slide DeckPowered by Get GeneDx Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeneDx and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataWGS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.WGS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. GeneDx Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $0.97 EPSNext Year EPS Consensus Estimate $2.09 EPS GeneDx Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025$0.10$0.50+$0.40$0.36$86.00M$102.69M4/30/2025Q1 2025$0.11$0.28+$0.17-$0.23$79.90M$87.12M2/18/2025Q4 2024$0.04$0.70+$0.66$0.23$82.24M$95.64M10/29/2024Q3 2024-$0.21$0.04+$0.25$0.39$64.98M$76.90M7/30/2024Q2 2024-$0.26-$0.11+$0.15$0.88$58.90M$70.51M4/29/2024Q1 2024-$0.68-$0.33+$0.35$0.12$49.80M$62.42M2/20/2024Q4 2023-$0.60-$0.59+$0.01-$0.26$57.00M$57.42M10/30/2023Q3 2023-$1.18-$0.82+$0.36-$53.80M$53.30M GeneDx Earnings - Frequently Asked Questions When did GeneDx announce their last quarterly earnings? GeneDx (NASDAQ:WGS) last announced its quarterly earning data on Tuesday, July 29, 2025. Learn more on WGS's earnings history. What guidance has GeneDx issued on next quarter's earnings? GeneDx updated its FY 2025 earnings guidance on Tuesday, July, 29th. The company issued revenue guidance of $400.0 million-$415.0 million, compared to the consensus revenue estimate of $368.6 million. Did GeneDx beat their earnings estimates last quarter? In the previous quarter, GeneDx (NASDAQ:WGS) reported $0.50 earnings per share (EPS) to beat the analysts' consensus estimate of $0.10 by $0.40. Learn more on analysts' earnings estimate vs. WGS's actual earnings. How can I listen to GeneDx's earnings conference call? The conference call for GeneDx's latest earnings report can be listened to online. Listen to Conference Call How can I read GeneDx's conference call transcript? The conference call transcript for GeneDx's latest earnings report can be read online. Read Transcript How much revenue does GeneDx generate each year? GeneDx (NASDAQ:WGS) has a recorded annual revenue of $362.32 million. How much profit does GeneDx generate each year? GeneDx (NASDAQ:WGS) has a recorded net income of -$52.29 million. WGS has generated $0.05 earnings per share over the last four quarters. What is GeneDx's price-to-earnings ratio? GeneDx (NASDAQ:WGS) has a trailing price-to-earnings ratio of 2,428.88 and a forward price-to-earnings ratio of 125.71. What is GeneDx's EPS forecast for next year? GeneDx's earnings are expected to grow from $0.97 per share to $2.09 per share in the next year, which is a 115.46% increase. More Earnings Resources from MarketBeat Related Companies GH Earnings Date OPCH Earnings Date RDNT Earnings Date BTSG Earnings Date SHC Earnings Date SGRY Earnings Date CON Earnings Date PRVA Earnings Date ADUS Earnings Date PGNY Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings Beat This page (NASDAQ:WGS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access